GGNDF Quote, Financials, Valuation and Earnings

Ascendis Pharma A/S has a net margin of 7.48% compared to GN Store Nord A/S's net margin of -13.56%. GN Store Nord A/S's return on equity of 6.73% beat Ascendis Pharma A/S's return on equity of -880.05%.

GN Store Nord A/S has a consensus price target of --, signalling downside risk potential of --. On the other hand Ascendis Pharma A/S has an analysts' consensus of $289.08 which suggests that it could grow by 25.56%. Given that Ascendis Pharma A/S has higher upside potential than GN Store Nord A/S, analysts believe Ascendis Pharma A/S is more attractive than GN Store Nord A/S.

GN Store Nord A/S has a beta of 0.409, which suggesting that the stock is 59.144% less volatile than S&P 500. In comparison Ascendis Pharma A/S has a beta of 0.490, suggesting its less volatile than the S&P 500 by 50.982%.

GN Store Nord A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 1.68%. Ascendis Pharma A/S offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GN Store Nord A/S pays -- of its earnings as a dividend. Ascendis Pharma A/S pays out -- of its earnings as a dividend.

GN Store Nord A/S quarterly revenues are $729.1M, which are larger than Ascendis Pharma A/S quarterly revenues of $288.1M. GN Store Nord A/S's net income of $54.5M is higher than Ascendis Pharma A/S's net income of -$39.1M. Notably, GN Store Nord A/S's price-to-earnings ratio is 20.00x while Ascendis Pharma A/S's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GN Store Nord A/S is 0.79x versus 16.96x for Ascendis Pharma A/S. Usually stocks with elevated PS ratios are considered overvalued.

Bavarian Nordic A/S has a net margin of 7.48% compared to GN Store Nord A/S's net margin of -21.14%. GN Store Nord A/S's return on equity of 6.73% beat Bavarian Nordic A/S's return on equity of 11.38%.

GN Store Nord A/S has a consensus price target of --, signalling downside risk potential of --. On the other hand Bavarian Nordic A/S has an analysts' consensus of -- which suggests that it could fall by --. Given that GN Store Nord A/S has higher upside potential than Bavarian Nordic A/S, analysts believe GN Store Nord A/S is more attractive than Bavarian Nordic A/S.

GN Store Nord A/S has a beta of 0.409, which suggesting that the stock is 59.144% less volatile than S&P 500. In comparison Bavarian Nordic A/S has a beta of 1.273, suggesting its more volatile than the S&P 500 by 27.336%.

GN Store Nord A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 1.68%. Bavarian Nordic A/S offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GN Store Nord A/S pays -- of its earnings as a dividend. Bavarian Nordic A/S pays out -- of its earnings as a dividend.

GN Store Nord A/S quarterly revenues are $729.1M, which are larger than Bavarian Nordic A/S quarterly revenues of $220.2M. GN Store Nord A/S's net income of $54.5M is higher than Bavarian Nordic A/S's net income of -$46.6M. Notably, GN Store Nord A/S's price-to-earnings ratio is 20.00x while Bavarian Nordic A/S's PE ratio is 10.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GN Store Nord A/S is 0.79x versus 2.42x for Bavarian Nordic A/S. Usually stocks with elevated PS ratios are considered overvalued.

Genmab A/S has a net margin of 7.48% compared to GN Store Nord A/S's net margin of 2.93%. GN Store Nord A/S's return on equity of 6.73% beat Genmab A/S's return on equity of 17.69%.

GN Store Nord A/S has a consensus price target of --, signalling downside risk potential of --. On the other hand Genmab A/S has an analysts' consensus of $37.14 which suggests that it could grow by 35.04%. Given that Genmab A/S has higher upside potential than GN Store Nord A/S, analysts believe Genmab A/S is more attractive than GN Store Nord A/S.

GN Store Nord A/S has a beta of 0.409, which suggesting that the stock is 59.144% less volatile than S&P 500. In comparison Genmab A/S has a beta of 0.972, suggesting its less volatile than the S&P 500 by 2.827%.

GN Store Nord A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 1.68%. Genmab A/S offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GN Store Nord A/S pays -- of its earnings as a dividend. Genmab A/S pays out -- of its earnings as a dividend.

GN Store Nord A/S quarterly revenues are $729.1M, which are smaller than Genmab A/S quarterly revenues of $1.1B. GN Store Nord A/S's net income of $54.5M is higher than Genmab A/S's net income of $31M. Notably, GN Store Nord A/S's price-to-earnings ratio is 20.00x while Genmab A/S's PE ratio is 17.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GN Store Nord A/S is 0.79x versus 4.75x for Genmab A/S. Usually stocks with elevated PS ratios are considered overvalued.

Zealand Pharma A/S has a net margin of 7.48% compared to GN Store Nord A/S's net margin of -550.12%. GN Store Nord A/S's return on equity of 6.73% beat Zealand Pharma A/S's return on equity of 51.22%.

GN Store Nord A/S has a consensus price target of --, signalling downside risk potential of --. On the other hand Zealand Pharma A/S has an analysts' consensus of -- which suggests that it could fall by -48.45%. Given that Zealand Pharma A/S has higher upside potential than GN Store Nord A/S, analysts believe Zealand Pharma A/S is more attractive than GN Store Nord A/S.

GN Store Nord A/S has a beta of 0.409, which suggesting that the stock is 59.144% less volatile than S&P 500. In comparison Zealand Pharma A/S has a beta of 0.884, suggesting its less volatile than the S&P 500 by 11.553%.

GN Store Nord A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 1.68%. Zealand Pharma A/S offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GN Store Nord A/S pays -- of its earnings as a dividend. Zealand Pharma A/S pays out -- of its earnings as a dividend.

GN Store Nord A/S quarterly revenues are $729.1M, which are larger than Zealand Pharma A/S quarterly revenues of $10.7M. GN Store Nord A/S's net income of $54.5M is higher than Zealand Pharma A/S's net income of -$59.1M. Notably, GN Store Nord A/S's price-to-earnings ratio is 20.00x while Zealand Pharma A/S's PE ratio is 3.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GN Store Nord A/S is 0.79x versus 2.21x for Zealand Pharma A/S. Usually stocks with elevated PS ratios are considered overvalued.